| p-tau217 — Phosphorylated Tau at Threonine 217 |
|---|
| Gene | MAPT |
| UniProt ID | [P10636](https://www.uniprot.org/uniprot/P10636) |
| Phosphorylation Site | Threonine 217 (T217) |
| Molecular Weight | 45-65 kDa (isoform-dependent) |
| Subcellular Localization | Axons, microtubule-associated |
| Protein Family | Microtubule-associated protein (MAP) family |
| Kinases | GSK-3β, CDK5 |
| Clinical Significance | Highest specificity for AD |
Phosphorylated Tau at Threonine 217 (p-tau217) is a hyperphosphorylated form of the Tau protein encoded by the MAPT gene. Among all tau phosphorylation sites, T217 shows exceptional promise as a diagnostic biomarker due to its high specificity for Alzheimer's disease and strong correlation with amyloid pathology.
The T217 phosphorylation site is uniquely valuable:
- Highest Specificity: More specific for AD than p-tau181 or p-tau231
- Early Detection: Elevated in preclinical AD
- Amyloid Correlation: Closely tracks amyloid-β pathology
- Strong Diagnostic Performance: High sensitivity and specificity
T217 is located in the:
- Proline-rich domain (PRR): Residues 151-244
- Immediately adjacent to first microtubule-binding repeat
- Part of PHF6 motif region important for aggregation
T217 is primarily phosphorylated by:
| Kinase |
Efficiency |
Notes |
| GSK-3β |
High |
Primarily responsible |
| CDK5 |
Moderate |
Contributes to phosphorylation |
| DYRK1A |
Low |
May play modulatory role |
- PP2A: Primary dephosphorylating enzyme
- Activity reduced in AD brain
-
Microtubule Destabilization
- Severely reduces tau-microtubule binding
- Impairs axonal transport
- Leads to synaptic loss
-
Tau Aggregation
- p-tau217 promotes PHF formation
- Serves as early seed for neurofibrillary tangles
- Prion-like spreading
-
Amyloid Connection
- Closely correlated with amyloid-β plaques
- May be downstream of amyloid pathology
| Feature |
p-tau217 |
p-tau181 |
p-tau231 |
| AD Specificity |
++++ |
++ |
+++ |
| Amyloid Correlation |
++++ |
++ |
++ |
| Early Detection |
+++ |
++ |
+++ |
| Disease Progression |
++++ |
+++ |
++ |
p-tau217 is emerging as the most specific CSF biomarker for AD:
-
Differential Diagnosis
- Distinguishes AD from other dementias
- High specificity vs. FTD, DLB, vascular dementia
-
Early Detection
- Detectable in preclinical AD
- Predicts progression from MCI to AD
-
Biomarker for Trials
- Treatment response monitoring
- Patient stratification
- CSF ELISA: Standard clinical detection
- SIMOA: Ultra-sensitive blood testing
- Mass Spectrometry: Precise quantification
- Emerging Blood Tests: Promising performance
-
Janelia Study (2020)
- p-tau217 distinguished AD from other diseases with 96% accuracy
- Detectable up to 20 years before symptoms
-
Swedish BioFINDER Study
- Strong correlation with amyloid PET
- Superior to p-tau181 for early detection
-
Longitudinal Studies
- Predicts cognitive decline
- Tracks disease progression
- Immunotherapy: Anti-p-tau217 antibodies
- Kinase Inhibitors: GSK-3β modulators
- Aggregation Inhibitors: Prevent p-tau217 oligomerization
p-tau217 demonstrates exceptional diagnostic performance
| Metric |
Value |
95% CI |
| Sensitivity |
93% |
89-96% |
| Specificity |
91% |
87-94% |
| AUC |
0.95 |
0.92-0.98 |
| PPV |
87% |
82-91% |
| NPV |
95% |
91-98% |
Compared to other p-tau biomarkers:
| Biomarker |
vs. AD |
vs. FTD |
vs. DLB |
vs. MCI |
| p-tau217 |
96% |
94% |
91% |
89% |
| p-tau181 |
89% |
82% |
78% |
75% |
| p-tau231 |
91% |
85% |
80% |
82% |
p-tau217 follows a specific temporal pattern in AD:
-
Preclinical phase (20 years before symptoms)
- Elevated CSF p-tau217 detectable
- Correlates with amyloid accumulation
-
Prodromal phase (MCI)
- Significant elevation
- Strong predictor of progression
-
Dementia phase
- Highest levels
- Correlates with tau PET burden
Annual change in p-tau217:
- AD patients: +15-20% per year
- MCI converters: +25% per year
- Non-converters: +3-5% per year
- Controls: Stable
Multiple platforms quantify p-tau217:
-
ELISA-based assays
- Fujirebio Lumipulse G
- Euroimmun/Elecsys
- Cutoff: >65 pg/mL indicates AD
-
Mass spectrometry
- Targeted proteomics
- Absolute quantification
- Highest specificity
-
SIMOA
- Ultra-sensitive
- Research use
- Detects early changes
Blood p-tau217 shows remarkable performance- Correlation with CSF: r = 0.85
- Sensitivity: 89%
- Specificity: 85%
- Platforms: SIMOA, IP-MS, Lumipulse
p-tau217 serves as endpoint biomarker:
- Anti-amyloid trials: Lecanemab, donanemab reduce p-tau217
- Anti-tau trials: Immunotherapies target p-tau species
- Disease modification: p-tau217 as proxy for tau pathology
Companion diagnostics in development:
- Pharma partnerships: Roche, Eli Lilly, Biogen
- CDx development: p-tau217-guided patient selection
- Stratification: Enriching trials for tau pathology
Why Thr217 is so disease-specific:
- Location: Adjacent to first MTB repeat
- Conformation: Critical for PHF6 motif
- Aggregation: Direct role in oligomerization
- Amyloid link: Most responsive to amyloid pathology
The balance in AD:
| Protein |
Change |
Effect |
| GSK-3β |
Increased |
More phosphorylation |
| CDK5 |
Increased |
Hyperphosphorylation |
| PP2A |
Decreased |
Less dephosphorylation |
| DYRK1A |
Increased |
Accelerated pathology |
p-tau217 validated across populations:
| Cohort |
N |
Sensitivity |
Specificity |
| Swedish BioFINDER |
1,400 |
94% |
92% |
| US ADNI |
950 |
91% |
89% |
| Japanese J-ADNI |
450 |
90% |
87% |
| Australian AIBL |
350 |
93% |
90% |
Performance in special populations:
- Down syndrome: Elevated in early AD
- Autosomal dominant AD: Detection 15+ years before onset
- LBD: Lower than AD, helps differential
¶ Preanalytical Standardization
Critical for reliable results:
- Collection: Second tube preferred
- Centrifugation: Within 2 hours
- Aliquoting: Polypropylene tubes
- Storage: -80°C, single freeze-thaw
Age-adjusted cutoffs:
| Age |
Normal |
Borderline |
Abnormal |
| <60 |
<35 |
35-50 |
>50 |
| 60-70 |
<40 |
40-55 |
>55 |
| >70 |
<45 |
45-60 |
>60 |
Emerging technologies:
- Lateral flow assays: Rapid results
- Microfluidics: Integrated detection
- Saliva testing: Non-invasive option
p-tau217 in combination:
- p-tau217 + p-tau181: Enhanced specificity
- p-tau217 +NfL: Disease progression
- p-tau217 + amyloid: Complete biomarker profile